Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
HNGE vs KLRA — Stock Comparison
Compare HNGE and KLRA side-by-side on StoQuant: HNGE Q-Score 62 vs KLRA 39; analyst signal 81 vs 84. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- HNGE — Hinge Health, Inc. · Health Care · market cap $9.00B · Q-Score verdict Buy (62.0, grade B) · analyst signal 81/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 93/100, competitive moat 88/100 · weakest signals: technicals 77/100. Full HNGE research.
- KLRA — Kailera Therapeutics, Inc. · Health Care · market cap $1.67B · Q-Score verdict Sell (39.0, grade D) · analyst signal 84/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 97/100, competitive moat 30/100 · weakest signals: technicals 17/100. Full KLRA research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: HNGE research · KLRA research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.